Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neha Mehta-Shah

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
JCI Insight|November 13, 2025
LAIR1 prevents excess inflammatory tissue damage in Staphylococcus aureus skin infection and Cutaneous T-cell LymphomaHannah K Dorando, Evan C Mutic, Kelly L Tomaszewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Blood Advances|October 23, 2023
Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphomaArmin Ghobadi, Nicole C Foley, Jared Cohen, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2025
Single Cell Resolution Tracking of Cutaneous T-Cell Lymphoma Reveals Clonal Evolution in Disease ProgressionHannah K Dorando, Jared M Andrews, Nicholas C Borcherding, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Blood|June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmarkJustin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Haematologica|September 14, 2023
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphomaTodd A Fehniger, Marcus P Watkins, Nkiruka Ezenwajiaku, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
JCI Insight|November 13, 2025
LAIR1 prevents excess inflammatory tissue damage in Staphylococcus aureus skin infection and Cutaneous T-cell LymphomaHannah K Dorando, Evan C Mutic, Kelly L Tomaszewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2026
Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell LymphomaNeha Mehta-Shah, Pier Luigi Zinzani, Eric D Jacobsen, et al.
Blood Advances|October 23, 2023
Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphomaArmin Ghobadi, Nicole C Foley, Jared Cohen, et al.
British Journal of Haematology|May 22, 2023
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphomaRobert Stuver, Steven M Horwitz, Ranjana H Advani, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2025
Single Cell Resolution Tracking of Cutaneous T-Cell Lymphoma Reveals Clonal Evolution in Disease ProgressionHannah K Dorando, Jared M Andrews, Nicholas C Borcherding, et al.
Blood Advances|October 1, 2020
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphomaPaola Ghione, Promie Faruque, Neha Mehta-Shah, et al.
Blood|June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmarkJustin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Haematologica|September 14, 2023
A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphomaTodd A Fehniger, Marcus P Watkins, Nkiruka Ezenwajiaku, et al.
Pageof 9